Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification

被引:14
|
作者
Arch, Jonathan R. S. [1 ]
Trayhurn, Paul [1 ]
机构
[1] Univ Buckingham, Clore Lab, Buckingham MK18 1EG, England
来源
FRONTIERS IN PHYSIOLOGY | 2013年 / 4卷
关键词
thermogenesis; energy expenditure; leanness; anti-obesity drug; genetically modified mouse; sympathomimetic; brown adipose tissue; leptin; BROWN ADIPOSE-TISSUE; BETA-ADRENOCEPTOR AGONIST; DIET-INDUCED OBESITY; INCREASES ENERGY-EXPENDITURE; SYMPATHETIC-NERVE ACTIVITY; ACTIVATED-RECEPTOR-GAMMA; RESTING METABOLIC-RATE; COLD-INDUCED INCREASE; FATTY-ACID OXIDATION; FOOD-INTAKE;
D O I
10.3389/fphys.2013.00064
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Many compounds and genetic manipulations are claimed to confer resistance to obesity in rodents by raising energy expenditure. Examples taken from recent and older literature, demonstrate that such claims are often based on measurements of energy expenditure after body composition has changed, and depend on comparisons of energy expenditure divided by body weight. This is misleading because white adipose tissue has less influence than lean tissue on energy expenditure. Application of this approach to human data would suggest that human obesity is usually due to a low metabolic rate, which is not an accepted view. Increased energy expenditure per animal is a surer way of demonstrating thermogenesis, but even then it is important to know whether this is due to altered body composition (repartitioning), or increased locomotor activity rather than thermogenesis per se. Regression analysis offers other approaches. The thermogenic response to some compounds has a rapid onset and so cannot be due to altered body composition. These compounds usually mimic or activate the sympathetic nervous system. Thermogenesis occurs in, but may not be confined to, brown adipose tissue. It should not be assumed that weight loss in response to these treatments is due to thermogenesis unless there is a sustained increase in 24-h energy expenditure. Thyroid hormones and fibroblast growth factor 21 also raise energy expenditure before they affect body composition. Some treatments and genetic modifications alter the diurnal rhythm of energy expenditure. It is important to establish whether this is due to altered locomotor activity or efficiency of locomotion. There are no good examples of compounds that do not affect short-term energy expenditure but have a delayed effect. How and under what conditions a genetic modification or compound increases energy expenditure influences the decision on whether to seek drugs for the target or take a candidate drug into clinical studies.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] ANTI-OBESITY DRUGS: WHAT RESEARCHERS WANT TO KNOW Four key questions on the new wave of anti-obesity drugs
    Prillaman, McKenzie
    NATURE, 2023, 620 (7972) : 28 - 30
  • [22] STRATEGIES AND TACTICS IN USE OF ANTI-OBESITY DRUGS
    BLUNDELL, JE
    LANCET, 1976, 1 (7963): : 804 - 804
  • [23] Novel anti-obesity drugs and plasma lipids
    Nikolic, Dragana
    Toth, Peter P.
    Ferlita, Alessandra
    Di Bartolo, Vittoria
    Montalto, Giuseppe
    Banach, Maciej
    Rizzo, Manfredi
    CLINICAL LIPIDOLOGY, 2014, 9 (02) : 179 - 187
  • [24] Novel anti-obesity drugs for people with HIV
    Chandiwana, Nomathemba
    Manne-Goehler, Jennifer
    Calmy, Alexandra
    Gaayeb, Lobna
    Venter, Willem
    LANCET HIV, 2024, 11 (08): : e502 - e503
  • [25] Anti-obesity drugs and neural circuits of feeding
    Adan, Roger A. H.
    Vanderschuren, Louk J. M. J.
    la Fleur, Susanne E.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (04) : 208 - 217
  • [26] Anti-obesity drugs: The present and future perspectives
    Lassen, Pierre Bel
    Aron-Wisnewsky, Judith
    CAHIERS DE NUTRITION ET DE DIETETIQUE, 2023, 58 (04): : 273 - 282
  • [27] A short history of serotonergic anti-obesity drugs
    Heal, D. J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 127 - 127
  • [28] Do we need anti-obesity drugs?
    Hainer, Vojtech
    Hainerova, Irena Aldhoon
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 8 - 20
  • [29] Who should pay for anti-obesity drugs?
    Sharma, AM
    NATIONAL MEDICAL JOURNAL OF INDIA, 1999, 12 (02): : 79 - 79
  • [30] HOW DO ANTI-OBESITY DRUGS WORK
    TURNER, P
    INTERNATIONAL JOURNAL OF OBESITY, 1978, 2 (03) : 343 - 348